Servier and Cure51 launch a research partnership to uncover new therapeutic targets in glioblastoma and develop new treatments derived from long term survivors’ biology
All the news from Servier
Servier expands its Golden Ticket program to China
Therapeutic adherence at the forefront of the new #BecauseISaySo campaign
How can we minimize the environmental footprint of a medicine without compromising its quality or safety?
#LegsFirst: Servier committed to make leg health a daily priority
Patient Voices: Caregiving, a full-time commitment
Oncology innovation gains momentum in Japan
Servier completes the acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business
One Job, Many Stories: celebrating women engineers across Servier Industry!